The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment

被引：0
|
作者：
Jin, Feng [1 ]
Robeson, Michelle [2 ]
Zhou, Huafeng [2 ]
Hisoire, Grace [1 ]
Ramanathan, Srini [1 ]
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
[2] Gilead Sci Inc, Seattle, WA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-CT204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT204
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics, Safety, and Tolerability of Tanimilast Following Single Administration in Subjects With Mild, Moderate, and Severe Renal Impairment
    Emirova, A.
    Piccino, A.
    Balzano, D.
    Rizzo, E.
    Bellatti, P.
    Rostello, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [22] The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone
    Bhattacharya, Chandrali S.
    Ericsson, Hans
    Johansson, Susanne
    Parkinson, Joanna
    Boca, Simina M.
    Yang, Ye
    Heijer, Maria
    Housler, Greggory
    Leonsson-Zachrisson, Maria
    Hartleib-Geschwindner, Judith
    Pizzato, Patricia Ely
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
  • [23] Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Severe Renal Impairment
    Butler, Kathleen
    Teng, Renli
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (09): : 1388 - 1398
  • [24] The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat
    Bhattacharya, Chandrali S.
    Pizzato, Patricia Ely
    Heijer, Maria
    Sunnaker, Mikael
    Holden, Julie
    Trebski, Monika
    Nelander, Karin
    Ali, Hodan
    Genov, Diyan K.
    Aurell, Malin
    Collen, Anna
    Ericsson, Hans
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (12) : 3212 - 3220
  • [25] Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
    Landry, Ishani
    Aluri, Jagadeesh
    Hall, Nancy
    Filippov, Gleb
    Dayal, Satish
    Moline, Margaret
    Reyderman, Larisa
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (02):
  • [26] THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT.
    Xin, Y.
    Collins, H.
    Cheng, F.
    Kwan, E.
    Ramanathan, S.
    Silverman, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S88 - S88
  • [27] Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
    Stephen Weller
    Julie Borland
    Shuguang Chen
    Mark Johnson
    Paul Savina
    Brian Wynne
    Toshihiro Wajima
    Amanda F. Peppercorn
    Stephen C. Piscitelli
    European Journal of Clinical Pharmacology, 2014, 70 : 29 - 35
  • [28] Lubeluzole pharmacokinetics in subjects with mild, moderate and severe renal impairment.
    Burstein, AH
    Lee, PID
    Gajjar, D
    Zhou, H
    Soo, Y
    Pesco-Koplowitz, L
    Hantson, L
    Woestenborghs, R
    Young, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 189 - 189
  • [29] Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
    Weller, Stephen
    Borland, Julie
    Chen, Shuguang
    Johnson, Mark
    Savina, Paul
    Wynne, Brian
    Wajima, Toshihiro
    Peppercorn, Amanda F.
    Piscitelli, Stephen C.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (01) : 29 - 35
  • [30] Safety and pharmacokinetics of gadobenate dimeglumine (GD) in subjects with renal impairment.
    Lambrecht, LJ
    Davies, BE
    McCloud, S
    Parker, JR
    Swan, SK
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 229 - 229
12345